TP53 and cancer: Surprisingly, PGCCs continue to be overlooked in most cancer-related articles that discuss the “bright” (pro-death) side of apoptosis in solid tumor therapy [97,98,99,100,101], the “dark” (pro-survival) side of apoptosis in cancer therapy [91,93], targeting the DNA damage response (e.g., the p53/p21 pathway) in cancer therapy [102,103,104,105,106,107], as well as numerous articles that highlight limitations of implementing anticancer strategies under the term “precision oncology” (reviewed in [22,26]).